Table 1.
Demographic and clinical variables, mean (standard deviation).
| HC (N = 31) | MCI-AD (N = 34) | MCI-LB (N = 37) | Group differences | |
|---|---|---|---|---|
| Male: female | 22:9 | 15:19 | 33:4 | χ2 = 16.8, p < 0.001a p(HC,MCI-AD) = 0.03 p(HC,MCI-LB) = 0.06 p(MCI-AD,MCI-LB) < 0.001 |
| Age | 73.7 (7.3) | 76.3 (7.6) | 74.7 (6.5) | F(2,99) = 1.1, p = 0.33b |
| AChEI | – | 6 (18%)e | 17 (46%)f | χ2 = 6.1, p = 0.01c |
| PD meds | – | 0e | 4 (11%)f | χ2 = 3.8, p = 0.052c |
| Years of education | 14.7 (4.0)g | 12.7 (3.3)h | 12.0 (2.9) | F(2,96) = 5.5, p = 0.005c p(HC,MCI-AD) = 0.06 p(HC,MCI-LB) = 0.005 p(MCI-AD,MCI-LB) = 1.0 |
| ACE-R | 92.7 (4.2) | 82.3 (8.7) | 83.5 (9.3) | t69 = 0.6, p = 0.58d |
| MMSE | 28.5 (1.1) | 26.9 (2.2) | 26.5 (2.5) | t69 = 0.9, p = 0.39d |
| UPDRS III | 5.5 (4.4) | 15.7 (14.0) | 23.5 (14.5) | t69 = 2.3, p = 0.02d |
| DCFS | – | 6.9 (1.9)i | 8.4 (3.3)k | t59 = 2.2, p = 0.03d |
| CAF total | – | 1.4 (2.7)i | 3.8 (4.3)k | t59 = 2.5, p = 0.01d |
| NPI total | – | 8.6 (9.3)i | 16.1 (13.1)k | t59 = 2.5, p = 0.02d |
| NEVHI | – | 0.8 (1.6)e | 2.9 (4.2) | t67 = 2.6, p = 0.01d |
ACE-R, Addenbrooke’s Cognitive Examination – Revised; AChEI, number of patients taking acetylcholinesterase inhibitors; CAF total, Clinician Assessment of Fluctuation total score; DCFS, Dementia Cognitive Fluctuation Scale; HC, healthy controls; MCI-AD, mild cognitive impairment with Alzheimer’s disease; MCI-LB, mild cognitive impairment with Lewy bodies; MMSE, Mini Mental State Examination; NEVHI, North-East Visual Hallucinations Interview; NPI, Neuropsychiatric Inventory; PD meds, number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III, Unified Parkinson’s Disease Rating Scale III (motor subsection)
Chi-square test HC, MCI-AD, MCI-LB; b Univariate ANOVA HC, MCI-AD, MCI-LB; c Chi-square test MCI-AD, MCI-LB; d Student’s t-test MCI-AD, MCI-LB.
N = 32, f N = 36, g N = 29, h N = 33, i N = 27, k N = 34